Hydralazine (IV — Acute Hypertension in Pregnancy)
Brand names: Apresoline
Intravenous hydralazine, a directly acting arteriolar vasodilator, used to control acute severe hypertension in pregnancy and the peripartum period, including pre-eclampsia and eclampsia.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Hydralazine relaxes arteriolar smooth muscle, reducing systemic vascular resistance and arterial pressure; the resulting fall in blood pressure can trigger a reflex tachycardia.
Prescribing in practice
- Blood pressure can fall abruptly, risking maternal hypotension and reduced uteroplacental perfusion with fetal distress, so it must be given by titrated doses with continuous maternal and fetal monitoring, and intravenous fluid co-loading is often considered.
- Reflex tachycardia, headache, flushing and fluid retention are common and the clinical picture can mimic worsening pre-eclampsia.
- It is one of several first-line options for acute severe hypertension in pregnancy and is administered only in a monitored obstetric or critical-care setting.
Monitoring
Monitor maternal blood pressure and heart rate frequently alongside cardiotocographic fetal monitoring during and after administration.
Counselling the patient
- This medicine is given by drip or injection to bring dangerously high blood pressure down quickly and protect you and your baby.
- You and your baby will be closely monitored throughout.
- Tell staff if you feel faint, develop a pounding heartbeat or a severe headache.
Evidence & guidelines
NICE guidance on hypertension in pregnancy lists intravenous hydralazine among first-line agents for acute severe hypertension, used with careful titration and monitoring.
Reference: NICE NG133 Hypertension in Pregnancy; RCOG Green-top 10A Eclampsia; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Murray Score for Acute Lung Injury (ALI/ARDS) · Respiratory Failure
- Simplified Acute Physiology Score 3 (SAPS 3) · ICU Scoring
- Killip Classification for Acute MI · Prognosis
- HEART Score for Major Adverse Cardiac Events · Chest Pain
- ADHERE Algorithm for Acute Decompensated Heart Failure · Risk Stratification
- Ottawa Heart Failure Risk Scale · Heart Failure
- Spinal Anaesthesia Hypotension Management · AAGBI; ASA
- Pre-Eclampsia / Eclampsia in ED · NICE NG133; RCOG Green-top 10A
- Suspected Ectopic Pregnancy · NICE NG126; RCOG Green-top 21
- Polycystic Ovary Syndrome (PCOS) · International PCOS Guideline 2023; NICE CKS
- Pre-eclampsia Management · NICE NG133 2019
- Ectopic Pregnancy · NICE CG154 / RCOG GTG 21